Fig. 3From: Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment centerNet cost of PSCK9 inhibitor therapy, based on CVD events estimated from the ACC/AHA risk calculator and present value of lifetime earnings (PVLE) in 61 patients assuming a 50Â % reduction in CVD events and lowered PVLE loss on PCSK9 inhibitor therapyBack to article page